Uric Acid Reducing Therapies

Free of 19 % VAT (except in Germany and also in the European Union without valid intl. VAT no), delivery costs do not apply.

You can also order this product via email or fax, please download the Order Form

Publisher: La Merie Publishing
Format: Word Table
Product Line: Target Pipeline List
Product Code: LMTPL039
Release Date: March of 2019
Loading...

Uric Acid Reducing Therapies – Target Pipeline List 03/2019

Targets: Uric Acid, Urate, Xanthine Oxidase, Uric Acid Transporter 1, URAT1

This Target Pipeline List provides an overview of biologic and chemical entities on the market or in development for treatment of hyperuricemia associated with gout and tumor lysis syndrome

Hyperuricemia may occur because of decreased excretion (underexcretors), increased production (overproducers), or a combination of these two mechanisms. Uric acid in the blood is saturated at 6.4-6.8 mg/dL at ambient conditions, with the upper limit of solubility placed at 7 mg/dL. Worldwide, the prevalence of hyperuricemia has increased substantially in recent decades. The progressive increase in serum levels of uric acid levels may be linked to the rising prevalence of overweight and obesity, as well as the increase in consumption of sugar-sweetened beverages, foods rich in purines, and alcohol.

Symptoms of hyperuricemia are those of gout and nephrolithiasis. Gout typically manifests as an acute monoarthritis, most commonly in the great toe and less frequently in the tarsal joint, knee, and other joints. Uric acid nephrolithiasis may manifest as hematuria; pain in the flank, abdomen, or inguinal region; and/or nausea and vomiting

The choice of urate-lowering medications includes uric acid depletion, inhibition of uric acid production or selective uric acid reabsorption inhibition. Treatment with uric acid reducing molecules is indicated for severe, refractory gout  and treatment or prophylaxis of acute hyperuricemia in patients with hematological malignancies at high or potential risk for tumor lysis syndrome (TLS).

La Merie Publishing offers a low-cost product service providing information about active R&D projects for a given target in the format of Word tables.

The Word document with the Table is delivered by e-mail within 24 hours after receipt of the confirmed order. Usually, delivery time is less than one hour if ordered during European business hours.

Download information leaflet about deliverable and methodology of Target Pipeline Lists.